Back to Public Benefits Corporation main page The Case Against Contracting with Doctors Community Healthcare Corporation (“DCHC”)Councilmember David CataniaFebruary 20, 2001
Home Bibliography Calendar ColumnsDorothy BrizillBonnie CainJim DoughertyGary ImhoffPhil MendelsonMark David RichardsSandra Seegars
DCWatch ArchivesCouncil Period 12Council Period 13Election 1998Election 2000
Elections Government and PeopleANC'sAuditorBoards and ComBusRegRefComChief Financial OfficerChief Management OfficerCity CouncilCongressControl BoardCourtsDC2000DC AgendaFire DepartmentFOI OfficersLegislationMayor's OfficeNeighborhood ActionNCRCPolice DepartmentPublic AdvocatePublic SchoolsPublic Service CommissionTax Rev CommTelephone DirectoryRegional Mobility
Shock and Awe And assessing the levels of general panic in the SARS marketplace so far, the pharmaceutical industries have every reason to expect significant financial returns from this latest campaign. Following the Pharma Biz ‘everybody panic’ template almost the letter, there have been frantic requests in Beijing and Hong Kong for ‘necessary’ testing kits, antibiotics and other medicines to reach the ‘stricken’ areas as soon as possible. His ‘n’ hers matching facemasks, along with masks for the household pets are selling very well. In many parts of South-east Asia, facemasks and household disinfectants have tripled in price. ABC News recently reported what is perhaps the first SARS murder - a fatal stabbing. The victim
Login HereRegister Now To access special member content and services, legislators, legislative staff and Foundation for State Legislatures sponsors must log in. (Clear this notice.) NCSLnet Registration HelpForgotten NCSLnet Password?
Health Finance Issues Updated: October 30, 2002 AT A GLANCE: Health Care in the United States now is a $1.5 trillion industry, encompassing significant portions of federal, state and local budgets, as well as a huge private sector market. The issues of growth, inflation, prices, sources of funding, as well as coverage and quality of services are central to much of today's health policy discussion. The following are a few overview statistics and projections, published March 2002 by the federal Centers for Medicare and Medicaid Services:
DAILY NEWSARTICLESARCHIVESCOLUMNSRESEARCHPRODUCTSMEDIA KITREADER SERVICE FUN AND GAMES --SUBSCRIPTIONS REPRINTS --EVENTS
Columns - Publication Date 5.7.2002 Viewpoint -- Pharmaceuticals Need To Wake Up If drug companies don't solve escalating pricing, someone else will. By Tonya Vinas
Normally, I'm not in favor of liability lawsuits. Most of the suits filed these days are frivolous, wasteful and beneficial to few while burdening many. Sometimes, though, lawsuits are the only way to shape equitable and efficient policies and practices in the absence of either the public or private sector doing so. I think this will be the case when it comes to the escalating price of prescription drugs in the United States. While our former and current presidents and both major political parties favor public policy changes to make drugs more affordable, no one in government has been able to solve this problem. The pharmaceutical companies are making their own weak attempts, but these address protectin
Politics: College Try: Jacob L. Vigdor on why universities should stop encouraging applicants to take the SATs over and over again Promise Keeper? Tova Wang on why Trent Lott's new position will allow him to make good on his pledges to African Americans -- if he meant what he said. Executive Privilege: Robert Kuttner on the prep-school president's ironic stance on affirmative action. The Rove Machine Rolls On: Robert Reich explains why Bush's consigliere is so adept at getting his way. Citizen Bane: The Arabs of East Jerusalem are only quasi-citizens. Has Israel alienated them at its ow
By Kim Dixon CHICAGO (Reuters) - Managed care stocks, a profitable refuge in the sinking stock market most of this year, have been weighed down in the past month as investors worry about how HMOs will grapple with soaring health costs and maintain fat profit margins.